Q-omics provides the consensus-scored VTCN1 profile across patient tissues and cancer cell-line models. VTCN1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, VTCN1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, VTCN1 RNA expression shows 12,217 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, KIRC, and TGCT as cancer lineages where VTCN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VTCN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VTCN1 survival associations across molecular data types. VTCN1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VTCN1 RNA expression–survival associations across cancer types. High VTCN1 expression shows unfavorable associations in DLBC, COAD, BLCA, SKCM and CHOL, but favorable associations in CESC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify DLBC as the clearest survival context for VTCN1 RNA expression.
This table summarizes VTCN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for VTCN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VTCN1 shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in THCA, LUAD and LUSC. The KIRC box plot shows higher VTCN1 RNA expression in normal versus tumor tissue (log2 FC = −4.722, t-test p < 0.001).
This table shows molecular features associated with VTCN1 in patient tissues and cancer cell lines. In patient samples, VTCN1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, VTCN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
